Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The use of platelet-rich fibrin in the surgical treatment of medication-related osteonecrosis of the jaw: 40 patients prospective study

J. Zelinka, J. Blahak, V. Perina, R. Pacasova, J. Treglerova, O. Bulik

. 2021 ; 165 (3) : 322-327. [pub] 20200626

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22005987

OBJECTIVES: Medication-related osteonecrosis of the jaw (MRONJ) is defined as exposed bone in the maxillofacial region persisting for more than eight weeks in patients who are or were treated with antiresorptive or antiangiogenic agents and had no radiation therapy to the craniofacial region or obvious metastatic disease of the jaws. It is a recognised side effect of antiresorptive or antiangiogenic medication. To date, there is no specific gold standard treatment for MRONJ cases. The aim of this study was to evaluate the successful rate of surgical treatment with adjuvant local application of platelet rich fibrin. METHODS: 40 patients treated with necrotic bone resection and adjuvant local application of platelet-rich fibrin (PRF) were included. Treatment outcomes were evaluated after 12 months. RESULTS: The outcome of surgical treatment was successful in 34 of all 40 patients (85%), in 12 months follow-up. If we evaluate only cases where removal of all necrotic bone was possible the success rate was increased to 94%. A significant association between size of necrotic bone and treatment response was found (P=0.014, Wilcoxon rank sum test with continuity correction). CONCLUSIONS: Surgical treatment of MRONJ with adjuvant local PRF application proved to be very effective and safe, especially in early stages when all necrotic bone can be easily removed.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc22005987
003      
CZ-PrNML
005      
20220224154547.0
007      
ta
008      
220207s2021 xr ad f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2020.023 $2 doi
035    __
$a (PubMed)32597421
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Zelinka, Jiří $7 xx0231273 $u Clinic of Oral and Maxillofacial Surgery, University Hospital Brno, Czech Republic
245    14
$a The use of platelet-rich fibrin in the surgical treatment of medication-related osteonecrosis of the jaw: 40 patients prospective study / $c J. Zelinka, J. Blahak, V. Perina, R. Pacasova, J. Treglerova, O. Bulik
504    __
$a Literatura
520    9_
$a OBJECTIVES: Medication-related osteonecrosis of the jaw (MRONJ) is defined as exposed bone in the maxillofacial region persisting for more than eight weeks in patients who are or were treated with antiresorptive or antiangiogenic agents and had no radiation therapy to the craniofacial region or obvious metastatic disease of the jaws. It is a recognised side effect of antiresorptive or antiangiogenic medication. To date, there is no specific gold standard treatment for MRONJ cases. The aim of this study was to evaluate the successful rate of surgical treatment with adjuvant local application of platelet rich fibrin. METHODS: 40 patients treated with necrotic bone resection and adjuvant local application of platelet-rich fibrin (PRF) were included. Treatment outcomes were evaluated after 12 months. RESULTS: The outcome of surgical treatment was successful in 34 of all 40 patients (85%), in 12 months follow-up. If we evaluate only cases where removal of all necrotic bone was possible the success rate was increased to 94%. A significant association between size of necrotic bone and treatment response was found (P=0.014, Wilcoxon rank sum test with continuity correction). CONCLUSIONS: Surgical treatment of MRONJ with adjuvant local PRF application proved to be very effective and safe, especially in early stages when all necrotic bone can be easily removed.
650    _2
$a inhibitory angiogeneze $x terapeutické užití $7 D020533
650    12
$a bisfosfonátová osteonekróza čelistí $x farmakoterapie $x chirurgie $7 D059266
650    _2
$a lidé $7 D006801
650    _2
$a čelisti $7 D007568
650    12
$a fibrin bohatý na krevní destičky $7 D000073183
650    _2
$a prospektivní studie $7 D011446
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Blahák, Jiří, $d 1986- $7 xx0195644 $u Clinic of Oral and Maxillofacial Surgery, University Hospital Brno, Czech Republic
700    1_
$a Peřina, Vojtěch $7 xx0143386 $u Clinic of Oral and Maxillofacial Surgery, University Hospital Brno, Czech Republic
700    1_
$a Pacasová, Rita $7 xx0086998 $u Transfusion and Tissue Department, University Hospital Brno, Czech Republic
700    1_
$a Treglerová, Jana $7 xx0243154 $u Clinic of Oral and Maxillofacial Surgery, University Hospital Brno, Czech Republic
700    1_
$a Bulik, Oliver $7 xx0107917
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1213-8118 $g Roč. 165, č. 3 (2021), s. 322-327
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32597421 $y Pubmed
910    __
$a ABA008 $b A 1502 $c A 1502 $y p $z 0
990    __
$a 20220207 $b ABA008
991    __
$a 20220224154535 $b ABA008
999    __
$a ok $b bmc $g 1763637 $s 1157140
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 165 $c 3 $d 322-327 $e 20200626 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20220207

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace